-+ 0.00%
-+ 0.00%
-+ 0.00%

Novogenia Joins 10XREVIV as Partner for Planned GLP-1 Nutrition Study in Abu Dhabi

PUBT·11/12/2026 12:14:24
Novogenia Joins 10XREVIV as Partner for Planned GLP-1 Nutrition Study in Abu Dhabi
  • Novogenia will serve as exclusive technology and manufacturing partner for a planned Abu Dhabi clinical study under the 10XREVIV initiative.
  • The initiative involves M42, 10X Health and REVIV Global, supporting the company's international expansion strategy.
  • The study initially targets 500 participants to assess personalized nutritional support alongside GLP-1 therapy.
  • Its role covers DNA analysis and the development and production of personalized dietary supplements for participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2433766_en) on November 12, 2026, and is solely responsible for the information contained therein.